Abstract
Introduction: Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs.Areas covered: We provide an overview of the existing evidence regarding the use of MCDA in the appraisal of orphan drugs worldwide. Three databases (Pubmed, Embase, Web of Science) were searched for English, French and German literature published between January 2000 and April 2017. Full-text articles were supplemented with conference abstracts. A total of seven articles and six abstracts were identified.Expert commentary: The literature suggests that MCDA is increasingly being used in the context of appraising orphan drugs. It has shown itself to be a flexible approach with the potential to assist in decision-making regarding reimbursement for orphan drugs. However, further research regarding its application must be conducted.
| Original language | English |
|---|---|
| Pages (from-to) | 135-146 |
| Number of pages | 12 |
| Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
| Volume | 18 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Keywords
- Multi-criteria decision analysis
- MCDA
- orphan drugs
- rare diseases
- reimbursement
- appraisal
- systematic review
- HEALTH TECHNOLOGY-ASSESSMENT
- PRACTICES TASK-FORCE
- RARE DISEASES
- ANALYSIS MCDA
- REIMBURSEMENT SYSTEMS
- EVALUATING TREATMENTS
- EVIDEM FRAMEWORK
- CRITERIA
- CARE
- CONTEXT